Adaptive Biotech And Collaborators Demonstrate Value Of Immunosequencing For Diagnosis Of Cutaneous T-Cell Lymphoma

SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies and collaborators at Brigham and Women’s Hospital today announced publication of a study demonstrating that the company’s revolutionary immunosequencing platform, which utilizes next-generation sequencing and advanced bioinformatics to sensitively profile all of the T cells in a biological sample, adds value in delivering more definitive diagnoses of cutaneous T-cell lymphoma (CTCL).

Help employers find you! Check out all the jobs and post your resume.

Back to news